Table 1. Characteristics of Identified Studies on ADIPOQ +45T>G and MS risk.
| Author | Year | Country/Ethnicity | Diagnostic Criteria | Genotyping Method | MS | Control | Language | QA | APN/(μg/ml) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TT | GT | GG | TT | GT | GG | MS | Control | |||||||
| YAO M22 | 2004 | Chinese/EA | WHO,1999 | PCR-RFLP | 91 | 79 | 18 | 87 | 77 | 22 | in Chinese | 8 | 4.93 ± 3.31 | 9.29 ± 4.83 |
| LIU DX23 | 2006 | Chinese/EA | IDF, 2005 | PCR-RFLP | 73 | 66 | 17 | 69 | 53 | 11 | in Chinese | 7 | NA | NA |
| LI YP24 | 2010 | Chinese/EA | IDF, 2006 | PCR-RFLP | 69 | 54 | 14 | 56 | 60 | 15 | in Chinese | 6 | NA | NA |
| ZHU XW25 | 2010 | Chinese/EA | CDS, 2004 | TaqMan | 72 | 91 | 20 | 74 | 62 | 8 | in Chinese | 7 | NA | NA |
| CAI Q26 | 2010 | Chinese/EA | IDF, 2005 | PCR-RFLP | 15 | 18 | 5 | 26 | 20 | 4 | in Chinese | 6 | NA | NA |
| Ranjith N27 | 2011 | NA/SA | NCEP ATP III | TaqMan | 208 | 81 | 6 | 134 | 50 | 6 | in English | 8 | NA | NA |
| Ranjith N27 | 2011 | NA/SA | IDF | TaqMan | 204 | 79 | 7 | 138 | 52 | 5 | in English | 8 | NA | NA |
| BU RF28 | 2011 | Chinese/EA | CDS, 2004 | TaqMan | 76 | 97 | 22 | 79 | 67 | 10 | in Chinese | 7 | 6.85 ± 2.97 | 12.1 ± 5.75 |
| Leu HB-129 | 2011 | Chinese/EA | ATP III | TaqMan | 170 | 156 | 31 | 307 | 251 | 47 | in English | 8 | NA | NA |
| Leu HB-229 | 2011 | Chinese/EA | ATP III | TaqMan | 264 | 224 | 42 | 446 | 398 | 69 | in English | 8 | NA | NA |
| HUANG FZ30 | 2012 | Chinese/EA | IDF, 2005 | PCR-RFLP | 118 | 92 | 14 | 108 | 80 | 12 | in Chinese | 7 | NA | NA |
| WANG SJ21 | 2012 | Chinese/EA | WHO, 1999 | PCR-RFLP | 90 | 74 | 16 | 31 | 16 | 3 | in Chinese | 7 | 9.81 ± 0.55 | 13.32 ± 1.07 |
| LI XT31 | 2012 | Chinese/EA | CDS, 2004 | PCR-RFLP | 71 | 40 | 5 | 76 | 28 | 4 | in English | 7 | NA | NA |
| CHEN F-132 | 2012 | Chinese/EA | CDS, 2004 | PCR-RFLP | 53 | 49 | 5 | 59 | 35 | 8 | in Chinese | 7 | 8.46 ± 5.96 | 10.87 ± 3.61 |
| CHEN F-232 | 2012 | Chinese/EA | NA | PCR-RFLP | 68 | 19 | 6 | 59 | 35 | 8 | in Chinese | 7 | 10.04 ± 6.39 | NA |
| GAO M9 | 2013 | Chinese/EA | IDF | PCR-RFLP | 147 | 158 | 17 | 93 | 61 | 7 | in English | 8 | NA | NA |
| SHEN J* 33 | 2013 | Chinese/EA Chinese | CDS, 2004 | PCR-RFLP | 48 | 93 | 66 | 78 | 15 | 5 | in Chinese | 7 | 9.70 ± 1.46 | 11.85 ± 1.46 |
| XU J34 | 2013 | Chinese/EA | IDF, 2005 | TaqMan | 368 | 274 | 59 | 97 | 93 | 16 | in Chinese | 8 | 9.85 (9.35–10.38) | 15.46 (14.13–16.90) |
| Suriyaprom K35 | 2014 | Thailand/SEA | NCEP/ATP III | NA | 84 | NA | NA | 102 | NA | NA | in English | 6 | 7.9 (7.0–9.2) | 14.5 (12.7–16.2) |
Note: MS = Metabolic Syndrome; APN = adiponectin; NA = Not Available; EA = East Asians; SA = South Asians; SEA = Southeast Asians; QA = Quality Assessment; *the HUI nationality. Leu HB-1and Leu HB-2 represent two separate populations. CHEN F-1: metabolic syndrome; CHEN F-2: metabolic syndrome with coronary heart disease.